Form 4: Olema Pharmaceuticals Executive Granted Stock Options

David C. Myles, Chief Discovery & Non-Clinical Development Officer at Olema Pharmaceuticals, was granted stock options to purchase 205,000 shares of common stock.

Summary

• David C. Myles, an officer at Olema Pharmaceuticals, received stock options on February 28, 2025.
• The options grant him the right to purchase 205,000 shares of Olema Pharmaceuticals' common stock at an exercise price of $4.37 per share.
• The options vest over time, with 25% vesting on February 28, 2026, and the remaining options vesting monthly over the subsequent 48 months, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The stock option grant aligns the executive's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to attract and retain key talent, aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Pfizer also utilize stock options to incentivize their executives.
• The size of the grant and the vesting schedule are generally determined based on the executive's role, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to improve company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates